Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingdao Univ. HDAC6 compound 20c: sourced facts only. name: "Herein, we report a group of novel hydrophobic tag based HDAC6 degraders by modifying the structure of Nexturastat A and identified 20c as a lead compound which selectively degrades HDAC6 in vitro (half-degradation concentration = 1.1 μM) in a ubiquitin-proteasome system dependent manner without obviously impacting six other HDAC isoforms." [PMID:42593926]; target: "Herein, we report a group of novel hydrophobic tag based HDAC6 degraders by modifying the structure of Nexturastat A and identified 20c as a lead compound which selectively degrades HDAC6 in vitro (half-degradation concentration = 1.1 μM) in a ubiquitin-proteasome system dependent manner without obviously impacting six other HDAC isoforms." [PMID:42593926]; developer: "Department of Pharmacology, School of Pharmacy, Qingdao Medical College of Qingdao University, Qingdao University, Qingdao266073, China." [PMID:42593926]; stage: "In a dextran sulfate sodium (DSS)-induced colitis model, 20c alleviated disease symptoms, reduced colon shortening, and downregulated pro-inflammatory cytokines." [PMID:42593926]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingdao Univ. HDAC6 compound 20c.